MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings
MAIA Biotechnology, Inc. (MAIA)
Company Research
Source: Business Wire
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that two of the Company’s independent directors, Ramiro Guerrero, JD, LL.M. and Stan V. Smith, Ph.D., purchased MAIA’s common stock and warrants in each of the Company’s recent private placement closings which occurred on November 1, 2024, and December 13, 2024. Total gross proceeds to MAIA from the closings were $3.4 million.Mr. Guerrero purchased a total of 141,952 shares and 141,952 warrants for an aggregate purchase price of approximately $300,000. Dr. Smith purchased a total of 125,000 shares and 125,000 warrants for an aggregate purchase price of approximately $273,000.“As always, we much appreciate the continuing support by our directors and their commitment to our scientific innovation and successful clinical progress,” said Vlad Vitoc, M.D., CEO of MAIA.“I believe MAIA
Show less
Read more
Impact Snapshot
Event Time:
MAIA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MAIA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MAIA alerts
High impacting MAIA Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
MAIA
News
- MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings [Yahoo! Finance]Yahoo! Finance
- MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas [Yahoo! Finance]Yahoo! Finance
- MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade GliomasBusiness Wire
- MAIA Biotechnology Announces Private Placement of Approximately $950,000Business Wire
- MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung CancerBusiness Wire
MAIA
Earnings
- 11/12/24 - Beat
MAIA
Sec Filings
- 12/20/24 - Form 8-K
- 12/13/24 - Form 4
- 12/13/24 - Form 4
- MAIA's page on the SEC website